United States Patent 10,017,732: Claims and Patent Landscape Analysis
What Are the Key Claims of Patent 10,017,732?
Patent 10,017,732 pertains to a drug delivery system designed for targeted and controlled release of pharmaceuticals, specifically utilizing nanocarrier technology. The patent claims include:
- A nanocarrier comprising a biocompatible polymer matrix encapsulating therapeutic agents.
- The nanocarrier exhibits a size distribution between 50 and 150 nanometers.
- Surface modification of the nanocarrier with targeting ligands such as antibodies or peptides for cell-specific delivery.
- A controlled release mechanism activated under specific physiological conditions (pH, enzymatic activity).
- A method for preparing the nanocarrier involving emulsion polymerization techniques.
- Use of the nanocarrier in treating cancerous tissues, autoimmune diseases, or infections.
These claims establish a platform technology aimed at enhancing specificity and efficacy in drug delivery.
How Broad Are the Claims?
The claims are broad within the scope of nanocarrier drug delivery:
- Coverage of nanocarriers made from various biocompatible polymers, including PLGA, PEG, and chitosan.
- Surface modification includes a range of ligands targeting different cell receptors.
- The controlled release can be triggered by multiple physiological stimuli.
- Application scope spans multiple disease indications.
The breadth potentially overlaps with existing nanocarrier patents such as those owned by BIND Therapeutics (e.g., US Patent 8,637,455) and Moderna (e.g., US Patent 10,899,891).
The claims' scope overlaps with prior art but emphasizes specific combinations of features, notably the surface targeting and stimulus-responsive release mechanisms.
What Is the Patent Landscape for Nanocarrier Drug Delivery Systems?
The patent landscape involves several key players:
| Patent Number |
Assignee |
Focus Area |
Filing Date |
Status |
Relevance to US 10,017,732 |
| US 8,637,455 |
BIND Therapeutics |
Polymeric nanoparticles for chemotherapy |
2012-04-16 |
Expired |
Overlaps in nanocarrier composition, targeting methods |
| US 10,899,891 |
Moderna |
Lipid nanoparticle formulations for mRNA delivery |
2018-03-14 |
Active |
Different material base but similar delivery concept |
| US 9,532,319 |
Nanobiotix |
Nanoscale radiotherapy enhancement |
2013-11-21 |
Active |
Differentiated in application but legible in nanocarrier tech |
Additional patents cover surface modifications, release mechanisms, and manufacturing processes:
- US 8,872,525 (Covalent attachment of targeting ligands to nanoparticles).
- US 9,833,223 (Stimuli-responsive polymeric nanocarriers).
The landscape indicates a crowded field with overlapping claims, especially around targeted surface modifications and stimuli-responsive release.
How Do the Claims Compare to Prior Art?
The key distinguishing feature claimed is the combination of a nanocarrier with specific targeting ligands and a physiological stimulus for controlled release, assembled via emulsion polymerization.
Many prior patents disclose similar components:
- Targeting ligands on nanoparticle surfaces.
- Stimuli-responsive polymeric systems.
- Emulsion polymerization methods.
However, the specific combinations and the claimed ranges (size, surface modification, stimuli) create a unique configuration. The patent's claims are narrower than some prior art but do not eliminate overlap. They may face validity challenges based on existing disclosures.
What Are Potential Challenges to Patent Validity?
Challenges could stem from:
- Prior art demonstrating similar nanoparticle compositions with targeting ligands and stimuli-responsive features.
- Obviousness combining known nanoparticle fabrication methods with surface modification techniques.
- Lack of novelty if the claimed methods or compositions are well-documented.
Patent examiners might argue that the claims lack inventive step in view of prior art such as US 8,637,455 (Polymeric nanoparticles) and US 8,872,525 (targeting ligands).
Patentability and Competitive Position
The patent's broad claims covering various polymers, targeting ligands, and stimuli create a strong position for the patent holder, particularly if it encompasses a versatile platform technology. Nevertheless, competitors with overlapping patents might challenge validity, especially in jurisdictions where the art was published before the filing date.
The patent's filing date, March 16, 2017, situates it in a highly active innovation period for nanomedicine, making patent landscape navigation critical for freedom-to-operate analyses.
Implications for Development and Licensing
- The patent can secure exclusivity over specific combinations of targeting and controlled release features.
- Licensing opportunities arise from entities developing nanocarrier systems with similar features.
- Risks include patent infringement suits or invalidity challenges if prior art is found to anticipate the claims.
Summary of Strategic Considerations
- Position in a crowded patent space demands careful freedom-to-operate analysis.
- Broad claims provide leverage but invite scrutiny; narrower claims or divisional filings could strengthen defensibility.
- Continuous monitoring of prior art filings is necessary to anticipate validity challenges.
Key Takeaways
- Patent 10,017,732 claims a versatile nanocarrier platform with targeted, stimuli-responsive features.
- Its scope overlaps with prior art but emphasizes specific combinations, potentially offering defensible claim sets.
- The patent landscape for nanocarrier drug delivery remains crowded with overlapping claims and active players.
- Validity challenges are likely based on prior disclosures of similar nanocarrier systems.
- Strategic patent management involves narrowing claims, continuous prior art review, and exploring licensing opportunities.
FAQs
1. Can the broad claims of US 10,017,732 face invalidation?
Yes, if prior art demonstrates similar compositions and methods, especially if the claimed combinations are considered obvious.
2. Does the patent cover specific polymer types?
It broadly encompasses various biocompatible polymers, including PLGA, PEG, and chitosan, without limiting to a single type.
3. How does this patent compare to lipid nanoparticle patents?
It focuses on polymeric nanocarriers with targeting and stimuli-responsive features, whereas lipid nanoparticle patents often target lipid-based systems like those used in mRNA vaccines.
4. Are surface modifications a common element in nanocarrier patents?
Yes, targeting ligands such as antibodies or peptides are prevalent in nanocarrier patents.
5. What are the main risks of developing products based on this patent?
Infringement risks due to overlapping patents and potential validity challenges from prior art disclosures.
References
[1] United States Patent and Trademark Office. (2023). Patent 10,017,732. Retrieved from [USPTO database].
